It was reported on Tuesday that the European Commission has granted final approval to US-based companies Mylan (NASDAQ: MYL) and Pfizer Inc (NYSE: PFE) for the proposed combination of their Upjohn business.
The European Commission offered conditional approval in April 2020 that was subject to the divestiture of certain of Mylan's products in Europe.
The European Commission approved the proposed divestiture buyers and Mylan signed the contract with those customers on terms that the European Commission has accepted. Both firms have already received approval from the Australian Competition and Consumer Commission and the New Zealand Commerce Commission related to combining this business.
Shanton Pharma completes SAP-001 End-of-Phase 2 meeting with US FDA
Eli Lilly's single-injection, once-monthly maintenance Omvoh regimen receives US FDA approval
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
AnnJi Pharmaceutical secures FDA Fast Track Designation for AJ201 in rare neuromuscular disease
Myosin Therapeutics' MT-125 granted US FDA Fast Track designation in glioblastoma
Boehringer Ingelheim's JASCAYD (nerandomilast) IPF treatment gains Chinese regulatory approval
Galera Therapeutics sells dismutase mimetics portfolio to Biossil in USD108.5m agreement